Long-Term Tadalafil Prescriptions Linked to Modest Glaucoma Increase in 74,000-Patient Review

Urologists and primary care physicians increasingly prescribe daily tadalafil as a well-tolerated, long-term solution for both erectile dysfunction and benign prostatic hyperplasia, viewing its systemic safety profile as firmly established. Conversely, neuro-ophthalmologists are now pointing to a dataset of nearly 74,000 men to argue that chronic phosphodiesterase type 5 (PDE5) inhibition subtly alters ocular blood flow, creating a modest but undeniable spike in glaucoma risk that requires immediate changes to screening protocols.[6]

The tension centers on a retrospective cohort study published in late August 2026. According to the findings highlighted by ScienceDaily, patients maintaining a long-term tadalafil regimen—commonly sold under the brand name Cialis—demonstrated a statistically significant increase in glaucoma diagnoses compared to non-users.[1]

Glaucoma, a condition characterized by damage to the optic nerve often linked to elevated intraocular pressure, typically develops without early symptoms. Healthline reports that while the exact mechanism remains under investigation, researchers suspect that the drug's primary function—relaxing smooth muscle and dilating blood vessels to improve blood flow—might inadvertently compromise the vascular autoregulation of the optic nerve over extended periods.[2]

The distinction between "as-needed" use and "daily" use is critical to the findings. Tadalafil is unique among PDE5 inhibitors, such as sildenafil, because of its prolonged half-life of 17.5 hours. This pharmacokinetic profile allows it to be prescribed as a low-dose daily pill, typically at 2.5 or 5 milligrams, for urinary symptoms associated with an enlarged prostate.[6]

Ophthalmology Times emphasizes that the elevated risk was specifically tied to this chronic, daily exposure among men treated for urinary symptoms, rather than intermittent use of the 10 or 20 milligram doses. The constant presence of the drug in the bloodstream means the ocular vasculature never fully returns to its baseline state, potentially leading to cumulative stress on the optic nerve head.[3]

The scale of the data provides significant weight to the ophthalmological warning. The review examined records from nearly 74,000 men, as reported by WOWO, making it one of the largest population-based analyses to cross-reference urological prescriptions with long-term visual outcomes.[5]

For patients, the clinical translation of this data is straightforward but requires coordination between specialties. Men currently taking daily Cialis do not need to abruptly halt their medication, which could cause a rapid return of severe urinary symptoms. Instead, they should ensure they undergo a dilated eye exam with an ophthalmologist or optometrist at least once every 12 months.[6]

NZ Optics adds that eye care providers should now explicitly ask older male patients about their use of erectile dysfunction and prostate medications during routine intake. Many patients omit these prescriptions from their general medical history, assuming urological drugs have no bearing on their vision.[4]

The pharmaceutical landscape is unlikely to shift immediately, as tadalafil remains highly effective for its primary indications since its initial U.S. Food and Drug Administration approval in 2003. The FDA already lists rare visual disturbances, such as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), on PDE5 inhibitor warning labels.

Moving forward, the burden of monitoring will fall largely on primary care providers to bridge the gap between urology and ophthalmology. If a patient on daily tadalafil begins showing early signs of elevated intraocular pressure, physicians will need to weigh the urological benefits against the visual risks, potentially switching to alternative treatments like alpha-blockers before irreversible nerve damage occurs.[6]